Raid Abu-Awwad, MD
Pulmonary Disease · Wichita, KSNPI 1386945392
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (51.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Intuitive Surgical at 57.4% of the total. Reporting peaked in 2022 at $3,109 and has fallen 96.2% since, to $118 in 2025.
Across 21 payments — averaging $276.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Pulmonx Corporation$1K
- AstraZeneca$595
- Boehringer Ingelheim$163
- Abbott$146
- Sanofi$125
- plus $374 from 4 others
What the payments were for
- Travel & lodging$89115%
- Food & beverage$1,90933%
- Education$3,00052%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 4 | $3,328 |
| Pulmonx Corporation | 4 | $1,070 |
| AstraZeneca | 5 | $595 |
| Boehringer Ingelheim | 2 | $163 |
| Abbott | 1 | $146 |
| Sanofi | 1 | $125 |
| Veran Medical Technologies, Inc. | 1 | $100 |
| Actelion Pharmaceuticals US, Inc. | 1 | $96 |
| GSK | 1 | $96 |
| Inari Medical, Inc. | 1 | $82 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$3,000
- CHARTIS CATHETER$1,029
- ZEPHYR DELIVERY CATHETER$1,029
- ZEPHYR ENDOBRONCHIAL VALVE$1,029
- PULMONX CHARTIS TABLET CONSOLE$1,029
- Da Vinci Surgical System$328
- DUPIXENT$250
- IMFINZI$249
- MitraClip System$146
- TEZSPIRE$125
- FASENRA$125
How this compares
$5,800 in reported general payments places this provider in the 70th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 721 | $516,700 |
| OfevNintedanib Esylate | 11 | $145,818 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 213 | $117,265 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 113 | $79,113 |
| NucalaMepolizumab | 14 | $59,345 |
| Breo ElliptaFluticasone/Vilanterol | 102 | $54,462 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 87 | $49,890 |
| Dupixent PenDupilumab | 12 | $47,114 |
| Spiriva RespimatTiotropium Bromide | 58 | $38,856 |
| Ambrisentan | 12 | $33,991 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 60 | $26,150 |
| Bosentan | 12 | $14,934 |
| Incruse ElliptaUmeclidinium Bromide | 23 | $14,323 |
| SymbicortBudesonide/Formoterol Fumarate | 44 | $14,085 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 361 | $9,636 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Nucala, Breo Ellipta, Incruse Ellipta | $96 | $766,8491,090 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $163 | $234,564156 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $595 | $119,348217 claims |
| Actelion Pharmaceuticals US, Inc.Bosentan | $96 | $14,93412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Wichita
- Abdel-Ghanie Abu-SamraWichita$60K
- Victor SalloumWichita$14K
- Ibrahim RaphaelWichita$13K
- Nader EldikaWichita$9K
- Dennis Oyieng'oWichita$9K
- Mark WencelWichita$9K
- John FlesherWichita$7K
- Youssef YammineWichita$6K
- Maged El-ZeinWichita$4K
- Son TruongWichita$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.